MedTrace Logo

Methylphenidate-Duloxetine Combinations for Cocaine Dependence

NCT02700711 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2018-06-26

No results posted yet for this study

Summary

This study will determine the influence of methylphenidate (e.g., Ritalin®) and duloxetine (Cymbalta®), alone and in combination, on the cocaine use as measured by self-report and urine drug screens.

Conditions

  • Cocaine Use Disorder

Interventions

DRUG

Methylphenidate

The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.

DRUG

Placebo

The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.

DRUG

Duloxetine

The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Kentucky

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02700711 on ClinicalTrials.gov